HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize?

Ballantyne, Christie M; Nambi, Vijay

Ballantyne, Christie M; Nambi, Vijay.

Affiliation

Ballantyne CM; From the Department of Medicine, Baylor College of Medicine (C.M.B., V.N.), the Texas Heart Institute (C.M.B.), and the Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center (V.N.) - all in Houston.
Nambi V; From the Department of Medicine, Baylor College of Medicine (C.M.B., V.N.), the Texas Heart Institute (C.M.B.), and the Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center (V.N.) - all in Houston.

N Engl J Med ; 390(17): 1622-1623, 2024 May 02.

Article in En | MEDLINE | ID: mdl-38587250

Subject(s)

Cardiovascular Diseases; Cholesterol, HDL; Hypolipidemic Agents; Lipid Metabolism; Humans; Biological Transport/drug effects; Cardiovascular Diseases/prevention & control; Cholesterol Ester Transfer Proteins/antagonists & inhibitors; Cholesterol, HDL/blood; Cholesterol, HDL/metabolism; Hypolipidemic Agents/pharmacology; Hypolipidemic Agents/therapeutic use; Lipid Metabolism/drug effects; Randomized Controlled Trials as Topic

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Cardiovascular Diseases / Lipid Metabolism / Cholesterol, HDL / Hypolipidemic Agents Limits: Humans Language: En Journal: N Engl J Med Year: 2024 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google